BamSEC and AlphaSense Join Forces
Learn More

Vaxcyte Inc.

NASDAQ: PCVX    
Share price (12/20/24): $86.53    
Market cap (12/20/24): $10.8 billion
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.27
from 10-K 10 pages Vaxcyte, Inc. Rsu Award Grant Notice – NON-U.S
12/34/56
EX-10.26
from 10-K 10 pages Vaxcyte, Inc. Stock Option Grant Notice – NON-U.S
12/34/56
EX-10.23
from 10-K 5 pages First Amendment to Lease
12/34/56
EX-10.21
from 10-K 3 pages Amendment No. 1 to the License Agreement Between Columbia Sutrovax, Inc. and the Regents of the University of California for Ucsd Case No. Sd2012-011
12/34/56
EX-10.19
from 10-K 44 pages Manufacturing Rights Agreement
12/34/56
EX-10.14
from 10-K 51 pages Pre-Commercial Services and Commercial Manufacturing Supply Agreement
12/34/56
EX-10.12
from 10-K 34 pages Master Services Agreement for Drug Product Development and Manufacturing
12/34/56
EX-10.3
from 10-Q 10 pages Third Amendment to Amended and Restated Sutrovax Agreement
12/34/56
EX-10.2
from 10-Q 9 pages Consent to Assignment and First Amendment
12/34/56
EX-10.1
from 10-Q 67 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Both (I) Not Material and (II) Is the Type That the Registrant Treats as Private or Confidential. Assignment and Assumption of Lease
12/34/56
EX-10.2
from 10-Q 6 pages Vaxcyte, Inc. Stock Option Grant Notice
12/34/56
EX-10.1
from 10-Q 30 pages Vaxcyte, Inc. 2020 Equity Incentive Plan Adopted by the Board of Directors: June 4, 2020 Approved by the Stockholders: June 4, 2020
12/34/56
EX-10
from 10-Q 28 pages Development and Manufacturing Services Agreement
12/34/56
EX-10
from 10-K 12 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Both (I) Not Material and (II) Is the Type That the Registrant Treats as Private or Confidential
12/34/56
EX-10
from 10-K 29 pages Supply Agreement
12/34/56
EX-10
from 10-K 31 pages Master Services Agreement for Drug Product Development and Manufacturing
12/34/56
EX-10
from 10-K 54 pages Development and Manufacturing Services Agreement
12/34/56
EX-10
from 10-K 5 pages The Company Is Excited About Your Joining and Looks Forward to a Mutually Beneficial and Productive Relationship. Nevertheless, You Should Be Aware That Your Employment With the Company Is for No Specified Period and Constitutes At‑will Employment. as a Result, You Are Free to Resign at Any Time, for Any Reason or for No Reason. Similarly, the Company Is Free to Conclude Its Employment Relationship With You at Any Time, With or Without Cause, and With or Without Notice. We Request That, in the Event of Resignation, You Give the Company at Least Two Weeks’ Notice
12/34/56
EX-10.1
from 10-Q 58 pages Development and Manufacturing Services Agreement
12/34/56
EX-10.2
from 10-Q 29 pages Master Services Agreement for Drug Product Development and Manufacturing
12/34/56